News
LivaNova Receives 510(k) Clearance for ECMO from FDA for LifeSPARC, the Next-generation Advanced Circulatory Support System
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received 510(k) clearance for extracorporeal membrane oxygenation (ECMO) from the U.S
Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
Novocure (NASDAQ: NVCR) today announced 25 abstracts on Tumor Treating Fields (TTFields) therapy will be featured at the Society for Neuro-Oncology (SNO) 2022 Annual Meeting from Nov. 16 to Nov. 20
EQS-News: BRAIN Biotech AG: MP Beteiligungs-GmbH Increases Stake in BRAIN Biotech AG
Agilent Announces Cash Dividend of 22.5 Cents Per Share
Agilent Technologies Inc. (NYSE: A) today announced the company has increased its quarterly dividend to 22.5 cents per share of common stock, reflecting a 7% increase over the previous quarter. The
GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab
GeNeuro (Paris:GNRO)(Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
GeNeuro meldet erste Patientenrekrutierungen in allen fünf schweizerischen Zentren für die erste klinische Studie mit Temelimab zur personalisierten Medizin gegen Long COVID
GeNeuro (Euronext Paris: CH0308403085 - GNRO), ein biopharmazeutisches Unternehmen, das sich darauf konzentriert, die kausalen Faktoren zu stoppen, die das Fortschreiten von neurodegenerativen und
GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
Agilent to Present at the Evercore ISI HealthCONx Conference
Agilent Technologies Inc. (NYSE: A) today announced that Mike McMullen, president and chief executive officer, and Bob McMahon, chief financial officer, will present at the 5th Annual Evercore ISI
EQS-News: Expansion of the Management Board of M1 Kliniken AG
EQS-News: Abivax releases the results of its November 9, 2022 ad hoc ordinary and extraordinary general meeting
Simulations Plus and the University of Bath Awarded New FDA Grant
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that, through a joint proposal with
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-Adhoc: MagForce AG: Agreement in principle on the sale of business operations
Agilent Announces AssayMAP Bravo Protein Sample Prep Workbench 4.0
Agilent Technologies Inc. (NYSE: A) today announced the release of the AssayMAP Bravo Protein Sample Prep Workbench 4.0 software. This release adds 21 CFR Part 11 compliance-enabling features that
Charles River Laboratories to Present at November Investor Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:
-
Jefferies 2022 London Healthcare Conference in
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
EQS-News: M1 Kliniken AG announces figures for Q3 2022: Group continues the expansion course with development of a new country market
Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB
First half results 2022/23: Growth in all regions and further progress on strategic initiatives
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements
EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November 22, 2022
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the Wolfe